Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
STAT10h
Medicare removes sexual orientation, gender identity questions from enrollment forms
The U.S. agency that oversees Medicare is taking out questions on enrollment application forms that ask people about their ...
New cancer vaccine shows promising results for certain patients
There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...
manilatimes16h
FDA approves Roche's Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently ...
A New Mexico District Says It’s Reduced Harsh Discipline of Native Students. But the Data Provided Is Incomplete.
Following an investigation by New Mexico In Depth and ProPublica, Gallup-McKinley County says it cut down on long-term ...